• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO and CFO

Share

Excerpt

In this presentation by Carl Zeiss Meditec AG, CEO and CFO delivered a comprehensive summary of the company’s financial results for the first nine months of the fiscal year 2022/23. Notably, the company registered double-digit top-line growth for another quarter, a testament to the relentless efforts of its operations team amidst complex supply chain conditions. The team has made some progress on delivery times, but more work must be accomplished.

 

Investments continue to flow into key areas, including research and development and sales and marketing, reflecting the company’s commitment to innovation and market presence. On EBIT, the company registered slight growth in Q3 compared to the previous year. However, margins remain under pressure due to a mix of strategic investments and product mix considerations.

 

The company’s focus for the coming period is twofold: decrease the order backlog to bring delivery times to normal levels and manage uncertainties like high levels of consumable stocks and pending price regulation for intraocular lenses in China. Despite these challenges, the management is confident of achieving their full-year revenue targets of 2.1 billion Euros and an EBIT margin of 17 to 20%, albeit likely at the lower end of this range.

 

The CEO and CFO emphasised their strategic investments and ongoing acquisitions, setting the stage for future growth and scalability. While acknowledging the year’s challenges, including geopolitical issues and high inflation, they expressed confidence that the strategy’s rewards would become increasingly visible in the years ahead.

Chapters

  • About the 9M – 2022/23
  • Earnings Development
  • Expectations for Q4 2022/23 and 2023/24
  • CEO Remarks

Resources

Presentation
Carl Zeiss Meditec Video Hub
Podcast

Host

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Linkedin

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Linkedin Envelope

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

August 4, 2023

Duration

03:13

Director

Reviews for Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO and CFO

There are currently no reviews for Carl Zeiss Meditec AG Financial Results 9M 2022 /23 | Robust Growth and Strategic Plans with CEO and CFO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

Italy:

Poland:

VERTICALS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

💺 seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top
seat11a - Video Insights for European Financial Markets